News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
X4 Pharmaceuticals Gains EMA CHMP Support for Mavorixafor Approval
X4 Pharmaceuticals has received a positive opinion from the EMA CHMP for Mavorixafor, marking a significant step towards approval for treating WHIM Syndrome. This development has important implications for investors and pharmaceutical teams.
Europe's Drug Innovation Edge at Risk: Insights from Dutch Industry Group
A recent report from a Dutch industry group highlights significant risks to Europe's drug innovation landscape, particularly concerning clinical trials. This article explores the implications for business development teams, investors, and analysts.
The Future of European Medicine: The Role of Clinical Research
This article discusses the pivotal role of clinical research in shaping the future of European medicine, highlighting its implications for investors and pharmaceutical teams.
Breast Cancer Insights: Key Abstracts for ESMO 2026
Experts preview key abstracts at the upcoming ESMO Breast Cancer Congress, highlighting their potential impact on oncology research and investment.
Q1 2026 Life Sciences Law Update: Clinical Trials Insights
This article provides a comprehensive update on life sciences law as it pertains to clinical trials in Q1 2026, highlighting key implications for stakeholders.
EMA's Political Agreement on Critical Medicines Act: Market Implications
The EMA has welcomed a political agreement on the Critical Medicines Act, marking a significant development for the pharmaceutical industry. This article analyzes the market implications for BD teams, investors, and analysts.
Regulatory Round-Up: Key Updates from 11 May 2026
Stay informed with the latest regulatory updates that could impact investment decisions and competitive strategies in the pharmaceutical sector.
Europe's Biotech Dilemma: Balancing Discovery and Scaling
Europe faces a critical challenge in biotech: balancing local discovery with the need to scale abroad. This article explores the implications for stakeholders.
Latest New Meds Recommended for Approval by EMA’s CHMP
The EMA’s CHMP has recommended several new medications for approval, signaling significant advancements in treatment options. This article explores the implications for the pharmaceutical landscape.
ESMO Updates Ovarian Cancer Guidelines: Key Changes and Implications
The ESMO updates to ovarian cancer guidelines signal significant changes in treatment protocols. This article explores the implications for the pharmaceutical sector.
Countries Compete to Reform Trials to Attract Global Sponsors
Countries are reforming their clinical trial processes to attract global sponsors. This article explores the competitive landscape and implications for the pharma sector.
Crinetics Reports $10.3M Palsonify Sales Amid 232 Enrollment Updates
Crinetics Pharmaceuticals reports $10.3M in Palsonify sales and updates on 232 enrollment forms. This article explores the implications for investors and BD teams.
20 Must-Read Highlights from ESMO Breast Cancer Congress 2026
Explore the most significant posts from the ESMO Breast Cancer Congress 2026, focusing on insights crucial for pharma teams and investors. Stay informed on the latest developments in oncology.
ISCT 2026: EU Manufacturing Innovations Day 1
ISCT 2026 Day 1 convened European cell therapy manufacturers to address automation, scale-up strategies, and regulatory compliance. Sessions highlighted manufacturing innovations and the critical role of process standardization in enabling commercial cell therapy production.
RAPS Euro Convergence: Key Regulatory Highlights for Pharma
RAPS Euro Convergence 2026 convenes European regulatory affairs professionals to address evolving EU pharmaceutical regulations, market access strategies, and emerging trends shaping drug development in European markets.
ISCT 2026: EU Manufacturing Innovations Day 1 Roundup
ISCT 2026's opening day highlighted critical manufacturing innovations and regulatory challenges facing European cell and gene therapy producers. Key themes included scalability, automation, supply chain resilience, and the need for harmonized EU regulatory standards.
RAPS Euro Convergence: Regulatory Insights and Key Takeaways
RAPS Euro Convergence 2026 convenes regulatory affairs professionals across Europe to address evolving pharmaceutical compliance frameworks, EMA guideline updates, and market access strategies in an increasingly complex EU regulatory environment.
European Research Revolution: Key Takeaways for Pharma
The European Research Revolution advances pharmaceutical innovation through translational research models and EU funding mechanisms, emphasizing cross-border collaboration and precision medicine initiatives across member states.
RAPS Euro Convergence: Regulatory Updates & Key Takeaways
RAPS Euro Convergence 2026 convenes European regulatory affairs professionals to address evolving EU pharmaceutical compliance frameworks, market access strategies, and emerging regulatory priorities shaping the future of pharmaceutical development and approval across Europe.
RAPS Euro Convergence: Key Regulatory Updates - Day 1
RAPS Euro Convergence 2026 opened with Day 1 sessions addressing regulatory harmonization, emerging compliance challenges, and innovative strategies for navigating the complex European pharmaceutical regulatory environment.